Guide
OTC Monograph Readiness — OMUFA and 21 CFR 330
If you manufacture over-the-counter (OTC) drugs that are marketed under an FDA monograph — sunscreens, antiseptics, antiperspirants, anti-acne, cough/cold actives, hand sanitizer, oral analgesics, and dozens of others — you operate under a regulatory regime that was rewritten in 2020. The CARES Act overhauled OTC monograph regulation, created OMUFA (the OTC Monograph User Fee program), and gave FDA new tools (Administrative Orders) to change monographs without rulemaking. Compliance now spans 21 CFR Part 330 (the monograph framework), 21 CFR 210/211 (drug cGMP), facility registration, listing, OMUFA fees, and the new Administrative Order docket. This guide explains what OTC monograph manufacturers actually owe FDA in 2026 and how to be ready without running on PDFs. Written for QA, regulatory and ops leads at OTC monograph drug manufacturers.
Start free trial Free trial, no credit card, onboard in days, not months.
What OTC monograph reform changed in 2020 (and why it still matters)
Before the CARES Act, FDA changed OTC monographs through full rulemaking — a process so slow that several monographs (sunscreen, hand sanitizer, topical antiseptics) sat in limbo for decades. OTC Monograph Reform gave FDA Administrative Orders: a faster mechanism to revise an OTC monograph, including in response to safety signals. The practical effect for manufacturers is that a monograph you've shipped under for 20 years can change — actives, concentrations, labeling, warnings — on a faster timeline than before. Compliance teams need a way to track open Administrative Order proceedings against the products they manufacture and to plan label and formula changes in advance, not after the order is final.
OMUFA fees and facility status
OMUFA — the OTC Monograph User Fee program — funds FDA's OTC monograph review activity. Manufacturers and contract manufacturers of OTC monograph drugs pay annual facility fees, and OMR (OTC Monograph Order Request) sponsors pay request fees. Facility fees are due on a federal-fiscal-year cycle; non-payment makes products produced at the facility misbranded. The compliance gap most manufacturers hit is administrative — the OMUFA invoice goes to one inbox, the responsible compliance officer doesn't see it, and a fee is missed. Modeling OMUFA facility status as a tracked obligation tied to the manufacturing site (with renewals and warnings) closes that gap.
Facility registration and drug listing (21 CFR 207)
OTC monograph drug manufacturers must register with FDA annually (Form FDA 2656/2657) and list each drug they manufacture, including monograph identifiers, NDC, active ingredients and labeling. Listings must be updated when product details change — a labeling revision, a discontinuation, or an additional active. Registration and listing are gating: FDA inspection priorities are partly driven by registration data, and unlisted drugs are considered misbranded. The common failure: a new SKU is launched and listing happens months later (or never), because nobody owned it.
Drug cGMP (21 CFR 211) — OTC is still a drug
An OTC monograph drug is a drug, so 21 CFR 211 cGMP applies in full — master and batch records, raw-material testing, in-process controls, finished-product testing, stability, complaints, recalls, and signed batch release. Manufacturers that came up through cosmetics or supplements and entered OTC via hand sanitizer or sunscreen frequently underestimate this. FDA inspections of OTC monograph manufacturers consistently surface findings in batch-record completeness, raw-material identity testing (e.g., glycerin / propylene glycol for diethylene glycol per FDA guidance), and stability programs. The fix is to operate the same eBR / lot-trace / stability discipline that a prescription manufacturer runs.
Labeling — the OTC Drug Facts box and Active Ingredients
Every OTC monograph drug must carry the Drug Facts panel (21 CFR 201.66) with the specific actives, purpose, uses, warnings, directions, and inactive ingredients in the format the monograph specifies. Label drift between FDA-approved artwork and what actually ships is one of the most common citations. The challenge for many OTC manufacturers — especially private-label/contract — is that the brand owner provides artwork and the manufacturer accepts it, without a structured check against the monograph requirements. The fix is to treat the Drug Facts box as a structured object validated against the monograph, not as a graphic.
Picking software that's actually OTC-monograph-aware
Most pharma QMS/MES vendors think 'OTC' is a synonym for cosmetics or supplements; most cosmetic/supplement vendors think OTC is 'cosmetics plus an active.' Neither is correct — OTC monograph drugs sit at the intersection of full drug cGMP and a monograph-driven label/formula regime that changes via Administrative Order. The right buy understands: monograph as a first-class object, OMUFA facility/fee tracking, structured Drug Facts panel, NDC/listing lifecycle, 21 CFR 211 batch execution, stability, and Administrative Order docket tracking. Ask any vendor: 'show me a product tied to its monograph and an open Administrative Order.' Most will improvise.
Standards covered in this guide
Each standard, retailer code or assurance scheme referenced above has its own deep-dive page with scope, audit detail and common pitfalls.
Where this lives in V5 Ultimate
The clauses above aren't theoretical — every one maps to a shipped module and an industry profile. Jump to the parts of the product that turn this guide into evidence on a Monday morning.
Modules that do the work
MES
21 CFR 211 cGMP execution for OTC monograph products.
Electronic batch records
Signed eBR per OTC monograph batch.
Document & label control
Drug Facts panel as a structured, validated object.
21 CFR Part 11
Closed-system attestation across registration, listing and batch records.
Compliance self-assessment
Score monograph readiness, OMUFA status and 211 cGMP together.
CAPA auto-routing
Monograph-related deviations and Administrative Order changes routed automatically.
Industries this hits hardest
Frequently asked
What's the difference between an OTC monograph drug and an OTC NDA drug?
Monograph drugs are sold under 21 CFR 330 — they don't need an individual NDA because they conform to a published monograph (actives, doses, indications, labeling). OTC NDA drugs are approved as individual new drug applications and sit outside the monograph system (Rx-to-OTC switches typically follow this path). Both are subject to 21 CFR 211 cGMP, but monograph drugs additionally must conform to monograph specifics and pay OMUFA fees.
We make hand sanitizer. Are we a monograph drug manufacturer?
Yes — hand sanitizer is regulated under the OTC monograph for topical antiseptics. The COVID-era guidance that loosened entry expired; manufacturers operating today owe full registration, listing, OMUFA fees, 21 CFR 211 cGMP, and a Drug Facts panel that matches the monograph.
Does cosmetics-style compliance (MoCRA) ever cover OTC products?
No — MoCRA explicitly excludes products regulated as drugs. A sunscreen, antiperspirant, anti-dandruff shampoo or anti-acne product is a drug under U.S. law and is regulated under the OTC monograph (and 21 CFR 211), not MoCRA. Many companies operate both regimes — cosmetics under MoCRA and drug-classified products under monograph cGMP.
How often does FDA inspect OTC monograph manufacturers?
Risk-based, with high-volume sites (hand sanitizer, sunscreen, antiperspirant) inspected more frequently than smaller niche manufacturers. Foreign manufacturers shipping into the U.S. are inspected on FDA's foreign-inspection program, which has expanded post-COVID. Plan for an inspection at least every 2–3 years; many OTC sites see annual visits.
See it on your shop floor.
Free trial, no credit card, onboard in days, not months.
Related reading
- 10 CFR 35 medical use readiness — NRC licensing for radiopharmaceuticals
- 21 CFR 111 Readiness: Dietary Supplement cGMP Subparts E & F
- 21 CFR 211 Drug cGMP Readiness Guide
- 21 CFR 212 PET drug cGMP readiness — FDA inspection playbook
- 21 CFR 589 BSE / Ruminant Feed Ban Readiness Guide
- 21 CFR Part 11 Readiness Guide for Regulated Manufacturers
Spot something off? .